Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
Displaying: 405 trials in your specialties ()
View trials across your selected specialties

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: 5-Azacytidine, Drug: Fludarabine, Drug: Melphalan, Drug: Alemtuzumab, Radiation: Total Body Irradiation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Weill Cornell Medical College, New York, New York, United States

Brief Summary

The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in complete remission (CR).

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Acute Myeloid Leukemia in Remission
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China

Brief Summary

Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent years. However, elderly patients ineligible for receiving high dose chemotherapy and allo-HSCT, have high relapse rate and treatment-related complications. Azacitidine (AZA), a listed hypomethylating agent in China in 2018, is the only approved demethylating drug in the treatment of AML, following the NCCN guidelines. In addition, lenalidomide(LEN) has been shown to rapidly enhance cytotoxic T- and natural killer (NK)-cell function and reduce relapse post-chemotherapy in patients with MM, also has substantial activity as a single agent in elderly patients with AML. Measurable residual disease (MRD) has been proven to be highly prognostic in quite a number clinical studies. This study is aimed to validate the efficacy and safety advantages of the maintenance therapy that contain AZA and LEN in elderly or unfit for intensive therapy patients with AML based on MRD monitoring.

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Neoplasms
View Full Trial
INTERVENTION

Drug: GSK3326595, Drug: 5-azacitidine, Drug: Best available care

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

GSK Investigational Site, Birmingham, Alabama, United States

Brief Summary

GSK3326595 is a potent, selective, reversible inhibitor of the protein arginine methyltransferase 5 (PRMT5)/Methylosome protein 50 (MEP50) complex that is being tested as an oral treatment for human participants with cancer. Myelodysplastic syndrome and acute myeloid leukemia are bone marrow neoplasms for which novel, effective therapies are desperately needed. This is an open-label, multicenter, multi-part study to evaluate the safety, tolerability, and clinical activity of GSK3326595 in participants with relapsed and refractory MDS, chronic myelomonocytic leukemia (CMML), and hypoproliferative AML that has evolved from an antecedent MDS. The study will be conducted in two parts and at the end of Part 1, if pre-specified criteria are met, then the study will be expanded with three additional parts that will be opened in parallel (Part 2A, 2B and 2C). Part 1 is composed of a single-arm dose expansion cohort to determine the clinical benefit rate of GSK3326595. Part 2A is a randomized head-to-head Phase II evaluation of GSK3326595 compared to investigator's choice of best available care (BAC). Part 2B is composed of an abbreviated series of dose escalation cohorts followed by a single-arm dose expansion cohort to determine the overall response rate of the combination of GSK3326595 plus 5-azaciditine in newly-diagnosed MDS. Part 2C is a single-arm dose expansion study to evaluate the clinical activity of single-agent GSK3326595 in participants with AML whose disease contains mutations in spliceosome proteins.

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients.

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Acute Myeloid Leukaemia
View Full Trial
INTERVENTION

Drug: AZD2811, Drug: Azacitidine, Drug: Venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Denver, Colorado, United States

Brief Summary

This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in relapsed/refractory acute myeloid leukaemia (AML) patients or treatment-naïve AML patients not eligible for intensive induction therapy. The study will also explore the potential clinical activity by assessing anti-tumour activity in patients. The study will be conducted in two parts, designated Part A, dose escalation, and Part B, dose expansion

Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Head and Neck Cancer
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Durvalumab, Drug: Tremelimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital, Boston, Massachusetts, United States

Brief Summary

This is a non-randomized, open-label, Phase Ib/II study to assess the safety and efficacy of azacitidine, durvalumab (MEDI4736), and tremelimumab combination therapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy for recurrent and/or metastatic disease. The clinical trial is studying drugs that can boost the participant's immune system against the cancer cells as a possible treatment for head and neck cancer. The study interventions involved in this study are: - Azacitidine (Vidaza) - Durvalumab (MEDI4736) - Tremelimumab

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Myelodysplastic Syndromes (MDS)
View Full Trial
INTERVENTION

Combination Product: Alvocidib Plus Decitabine or Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Chicago, Chicago, Illinois, United States

Brief Summary

Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS. Patients with IPSS-R intermediate and above MDS have an increased risk of developing AML and may be treated with the same chemotherapy regimens used in patients with AML. Eight Phase I or II clinical trials have been completed in patients with AML, totaling more than 400 patients with both relapsed/refractory or newly diagnosed AML. Preclinical studies have demonstrated that decitabine exposure increased the expression of NOXA, which is a specific antagonist of the survival factor MCL 1. Pharmacologic downregulation of MCL-1 via CDK 9 inhibition, as well as upregulation of the MCL-1 antagonist, NOXA, following decitabine exposure may result in enhanced antileukemic activity in MCL-1-dependent malignancies.

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Previously Untreated Acute Myeloid Leukemia
View Full Trial
INTERVENTION

Biological: Samalizumab (BAML-16-001-S1), Biological: BI 836858 (BAML-16-001-S2), Other: Laboratory Biomarker Analysis, Drug: Daunorubicin (BAML-16-001-S1), Drug: Cytarabine (BAML-16-001-S1), Drug: Azacitidine (BAML-16-001-S2), Drug: AG-221 (BAML-16-001-S3), Drug: Azacitidine (BAML-16-001-S3), Drug: Entospletinib (BAML-16-001-S4), Drug: Azacitidine (BAML-16-001-S4), Drug: Entospletinib (BAML-16-001-S5), Drug: Decitabine (BAML-16-001-S5), Drug: Entospletinib (BAML-16-001-S6), Drug: Daunorubicin (BAML-16-001-S6), Drug: Cytarabine (BAML-16-001-S6), Drug: Pevonedistat (BAML-16-001-S9), Drug: Azacitidine (BAML-16-001-S9), Drug: AG-120 (BAML-16-001-S16), Drug: Azacitidine (BAML-16-001-S16), Drug: Gilteritinib (BAML-16-001-S8), Drug: Decitabine (BAML-16-001-S8), Drug: Acalabrutinib (BAML-16-001-COV1), Other: Standard Therapy (BAML-16-001-COV1), Drug: AZD5153 (BAML-16-001-S10), Drug: Venetoclax (BAML-16-001-S10), Drug: TP-0903 (BAML-16-001-S14), Drug: Decitabine (BAML-16-001-S14)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic Arizona, Phoenix, Arizona, United States

Brief Summary

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Colorectal Cancer
View Full Trial
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Leukemia
View Full Trial
INTERVENTION

Drug: Azacitidine (AZA) Days 1 - 3, Drug: Decitabine (DAC), Other: Best Supportive Care (BSC), Drug: Azacitidine (AZA) Days 1 - 5

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moffitt Cancer Center, Tampa, Florida, United States

Brief Summary

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. This is an investigational study. Decitabine and azacitidine are both FDA approved and commercially available for use in patients with MDS. Giving these drugs on a different schedule than is standard is considered investigational. The study doctor can tell you how the study drugs are designed to work. Up to 240 participants will be enrolled in this multicenter study. Up to 157 will take part at MD Anderson.

Safety and Efficacy of IBI188 With Azacitidine in Newly Diagnosed Higher Risk MDS

  • Status
    Not yet recruiting
  • Phase
    Phase 1
  • Condition
    Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: IBI188+azacitidine, Drug: Drug:Azacitidine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Blood Diseases Hospital Chinese Academy Of Medical Science, Tianjin, China

Brief Summary

The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome